Friday, 17 December 2021

Home » , , , , » In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.

In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.

By  December 17, 2021  No comments
//

0 comments:

Post a Comment

');
?orderby=published&alt=json-in-script&callback=mythumb\"><\/script>");

Most Popular